Raymond James Financial Inc. Acquires Shares of 157,454 Bausch + Lomb Co. (NYSE:BLCO)

Raymond James Financial Inc. bought a new stake in shares of Bausch + Lomb Co. (NYSE:BLCO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 157,454 shares of the company’s stock, valued at approximately $2,844,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Blue Trust Inc. raised its position in shares of Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock worth $48,000 after acquiring an additional 1,004 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in Bausch + Lomb during the fourth quarter valued at $72,000. Commonwealth Equity Services LLC bought a new stake in shares of Bausch + Lomb during the 4th quarter valued at $181,000. Orion Portfolio Solutions LLC purchased a new stake in shares of Bausch + Lomb in the 4th quarter worth about $225,000. Finally, Renaissance Technologies LLC bought a new position in shares of Bausch + Lomb in the 4th quarter worth about $372,000. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BLCO has been the subject of a number of analyst reports. Royal Bank of Canada decreased their target price on shares of Bausch + Lomb from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Friday, April 4th. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a research note on Thursday, April 24th. Bank of America reduced their price target on Bausch + Lomb from $18.00 to $17.00 and set an “underperform” rating for the company in a report on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Bausch + Lomb in a research note on Tuesday, February 18th. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $15.00 price objective (down from $24.00) on shares of Bausch + Lomb in a research note on Friday, March 28th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $18.82.

Bausch + Lomb Trading Down 0.6 %

NYSE:BLCO opened at $13.65 on Tuesday. The company has a market cap of $4.82 billion, a PE ratio of -15.00, a price-to-earnings-growth ratio of 0.85 and a beta of 0.54. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The company has a 50 day simple moving average of $14.21 and a two-hundred day simple moving average of $17.10. Bausch + Lomb Co. has a 12 month low of $10.46 and a 12 month high of $21.69.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02. The company had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. Bausch + Lomb’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.24 earnings per share. Research analysts forecast that Bausch + Lomb Co. will post 0.74 earnings per share for the current year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.